Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease

Abstract: Bronchiolitis obliterans syndrome (BOS) is a severe form of chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic cell transplant (HCT), with a 5-year survival rate of 40%. Currently, there is no curative therapy for BOS. Preclinical data suggest that pirfenidone, an...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Husham Sharifi, Carson Tyler Moss, Zayan Musa, Alexander Bell, Christian O’Donnell, Carlos Hernandez Borges, Efthymia Iliana Matthaiou, Laura Johnston, Craig J. Galban, Ajay Sheshadri, Gregory Yanik, Guang-Shing Cheng, Joe L. Hsu
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-10-01
Saila:	Blood Advances
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2473952925003519
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!